Balversa (erdafitinib) — CareFirst (Caremark)

Initial criteria

• Diagnosis of metastatic non-small cell lung cancer with FGFR alterations

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on current regimen

Approval duration

12 months